(13)C-Urea breath test threshold calculation and evaluation for the detection of Helicobacter pylori infection in children

BACKGROUND: The (13)C-urea breath test (UBT) is performed in adults and children with epigastric pain for non-invasively diagnosing a suspected H. pylori infection. Criteria for UBT interpretation have not been generally agreed on and test reliability has not been established in children of different ages. This study aimed at identifying reliable UBT thresholds in children by using 251 UBTs in conjunction with reference histology and by analyzing 1232 UBTs. METHODS: At baseline and 30 and 60 minutes after the administration of 75 mg (13)C-urea to children and adolescents (0.25 to 18 years of age), the differences (Δ) of (13)CO(2)/(12)CO(2) ratio in exhaled air (δ) were determined by mass spectrometry. UBT Δδ value thresholds were calculated in random subgroups and evaluated in complementary subgroups using logistic regressions on reference histology or bimodal distribution analyses of Δδ values from UBTs alone. RESULTS: Δδ values were higher (median, 15.4‰) in positive (133/251, 53 %) than in negative histology (2.4‰). At 30 minutes, the calculated cut-off was 5.3‰ (mean regression determination R(2) = 0.91), and sensitivity (0.95), specificity (0.97), positive (0.97) and negative predictive values (0.95) were higher than at 60 minutes (threshold 6.8‰, R(2) = 0.85). Similar thresholds resulted from UBTs analysis (5.8‰ and 6.2‰) when sensitivity and specificity were maximized (concordance probabilities, 0.99 and 0.99). There was no systematic age effect. CONCLUSIONS: In children, (13)C UBT cut-offs were obtained and specially validated, entailing high accuracy of non-invasively testing for gastric H. pylori infection

Wirtschaftskontrolle durch Whistleblowing? : empirische Befunde zu Entscheidungsprozessen von Hinweisgebern

Akzeptierte ManuskriptversionManuskriptversion weicht in der Seitenzählung ab vom Origina

Bridging the gap:a review of dose investigations in paediatric investigation plans

Aims In the EU, development of new medicines for children should follow a prospectively agreed paediatric investigation plan (PIP). Finding the right dose for children is crucial but challenging due to the variability of pharmacokinetics across age groups and the limited sample sizes available. We examined strategies adopted in PIPs to support paediatric dosing recommendations to identify common assumptions underlying dose investigations and the attempts planned to verify them in children. Methods We extracted data from 73 PIP opinions recently adopted by the Paediatric Committee of the European Medicines Agency. These opinions represented 79 medicinal development programmes and comprised a total of 97 dose investigation studies. We identified the design of these dose investigation studies, recorded the analyses planned and determined the criteria used to define target doses. Results Most dose investigation studies are clinical trials (83 of 97) that evaluate a single dosing rule. Sample sizes used to investigate dose are highly variable across programmes, with smaller numbers used in younger children (< 2 years). Many studies (40 of 97) do not pre-specify a target dose criterion. Of those that do, most (33 of 57 studies) guide decisions using pharmacokinetic data alone. Conclusions Common assumptions underlying dose investigation strategies include dose proportionality and similar exposure−response relationships in adults and children. Few development programmes pre-specify steps to verify assumptions in children. There is scope for the use of Bayesian methods as a framework for synthesizing existing information to quantify prior uncertainty about assumptions. This process can inform the design of optimal drug development strategies

Germany’s Ecosystem Services – State of the Indicator Development for a Nationwide Assessment and Monitoring

The obligations of the EU Biodiversity Strategy 2020 are generating a need to create national maps and monitoring systems for the state of biodiversity and ecosystem services (ES) on the basis of indicators. The paper gives an overview of the ecosystem services indicators being developed for Germany in the context of ongoing research projects. Additionally, it provides the indicator specifications, which are aligned with the EU MAES framework concepts (initiative on Mapping and Assessment of Ecosystems and their Services). We illustrate aspects of data selection, calculation and negotiation procedures, results and target values in general and by way of examples. The German indicator-based approach presents measures and sums up ES in their spatial expression and temporal change and compares them with objectives. As far as possible, this is carried out according to the demand-supply concept. A prioritization of ES classes to be processed was carried out in the framework of an expert-based assessment. The results indicated that 21 of the 48 CICES classes (Common International Classification of Ecosystem Services) were most relevant for Germany in recent years. We proposed a total of 51 indicators, of which 14 indicators for 4 ES classes were accepted, implemented and published by the end of 2016. The development of ES maps and the indicator-based assessment on a national scale is a process. Consequently, the necessary further steps are shown

Health horizons: Future trends and technologies from the European Medicines Agency’s horizon scanning collaborations

In medicines development, the progress in science and technology is accelerating. Awareness of these developments and their associated challenges and opportunities is essential for medicines regulators and others to translate them into benefits for society. In this context, the European Medicines Agency uses horizon scanning to shine a light on early signals of relevant innovation and technological trends with impact on medicinal products. This article provides the results of systematic horizon scanning exercises conducted by the Agency, in collaboration with the World Health Organization (WHO) and the European Commission’s Joint Research Centre’s (DG JRC). These collaborative exercises aim to inform policy-makers of new trends and increase preparedness in responding to them. A subset of 25 technological trends, divided into three clusters were selected and reviewed from the perspective of medicines regulators. For each of these trends, the expected impact and challenges for their adoption are discussed, along with recommendations for developers, regulators and policy makers

The impact of episporic modification of Lichtheimia corymbifera on virulence and interaction with phagocytes

Fungal infections caused by the ancient lineage Mucorales are emerging and increasingly reported in humans. Comprehensive surveys on promising attributes from a multitude of possible virulence factors are limited and so far, focused on Mucor and Rhizopus. This study addresses a systematic approach to monitor phagocytosis after physical and enzymatic modification of the outer spore wall of Lichtheimia corymbifera, one of the major causative agents of mucormycosis. Episporic modifications were performed and their consequences on phagocytosis, intracellular survival and virulence by murine alveolar macrophages and in an invertebrate infection model were elucidated. While depletion of lipids did not affect the phagocytosis of both strains, delipidation led to attenuation of LCA strain but appears to be dispensable for infection with LCV strain in the settings used in this study. Combined glucano-proteolytic treatment was necessary to achieve a significant decrease of virulence of the LCV strain in Galleria mellonella during maintenance of the full potential for spore germination as shown by a novel automated germination assay. Proteolytic and glucanolytic treatments largely increased phagocytosis compared to alive resting and swollen spores. Whilst resting spores barely (1-2%) fuse to lysosomes after invagination in to phagosomes, spore trypsinization led to a 10-fold increase of phagolysosomal fusion as measured by intracellular acidification. This is the first report of a polyphasic measurement of the consequences of episporic modification of a mucormycotic pathogen in spore germination, spore surface ultrastructure, phagocytosis, stimulation of Toll-like receptors (TLRs), phagolysosomal fusion and intracellular acidification, apoptosis, generation of reactive oxygen species (ROS) and virulence